Does the media refer more to CTEC or SN?

In the previous week, Convatec Group had 1 more articles in the media than Smith & Nephew. MarketBeat recorded 2 mentions for Convatec Group and 1 mentions for Smith & Nephew. Convatec Group's average media sentiment score of 1.88 beat Smith & Nephew's score of 0.00 indicating that Convatec Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Convatec Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Smith & Nephew 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SN or NIOX more profitable?

NIOX Group has a net margin of 14.74% compared to Smith & Nephew's net margin of 10.08%. Smith & Nephew's return on equity of 12.25% beat NIOX Group's return on equity. Company Net Margins Return on Equity Return on Assets Smith & Nephew 10.08% 12.25% 4.51% NIOX Group 14.74% 10.01% 3.95%

Do analysts rate SN or TSTL?

Smith & Nephew currently has a consensus target price of GBX 1,293.33, suggesting a potential upside of 23.29%. Given Smith & Nephew's stronger consensus rating and higher possible upside, equities research analysts clearly believe Smith & Nephew is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, SN or TSTL?

Smith & Nephew has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew £7.08B 1.62 £382.79M £27.77 37.77 Tristel £49.54M 4.20 £6.54M £16.24 26.67

Is SN or TSTL more profitable?

Tristel has a net margin of 15.88% compared to Smith & Nephew's net margin of 10.08%. Tristel's return on equity of 23.64% beat Smith & Nephew's return on equity. Company Net Margins Return on Equity Return on Assets Smith & Nephew 10.08% 12.25% 4.51% Tristel 15.88% 23.64% 9.89%

Does the media refer more to SN or TSTL?

In the previous week, Smith & Nephew and Smith & Nephew both had 1 articles in the media. Smith & Nephew's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tristel 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SN or EKF?

In the previous week, Smith & Nephew and Smith & Nephew both had 1 articles in the media. EKF Diagnostics' average media sentiment score of 0.75 beat Smith & Nephew's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral EKF Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Smith & Nephew (SN) Competitors

GBX 1,050 +1.00 (+0.10%)

As of 10/14/2026

Compare

SN vs. CTEC, AMS, NIOX, TSTL, and EKF

Should you buy Smith & Nephew stock or one of its competitors? Smith & Nephew's main competitors and comparable companies include Convatec Group (CTEC), Advanced Medical Solutions Group (AMS), NIOX Group (NIOX), Tristel (TSTL), and EKF Diagnostics (EKF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Smith & Nephew compare to Convatec Group?

Convatec Group (LON:CTEC) and Smith & Nephew (LON:SN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Smith & Nephew has higher revenue and earnings than Convatec Group. Smith & Nephew is trading at a lower price-to-earnings ratio than Convatec Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Convatec Group	£2.49B	1.81	£188.35M	£6.20	37.84
Smith & Nephew	£7.08B	1.62	£382.79M	£27.77	37.77

Convatec Group has a beta of 0.765, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Smith & Nephew has a beta of 0.688, suggesting that its stock price is 31% less volatile than the broader market.

Convatec Group currently has a consensus target price of GBX 305.44, indicating a potential upside of 30.20%. Smith & Nephew has a consensus target price of GBX 1,293.33, indicating a potential upside of 23.29%. Given Convatec Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Convatec Group is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Convatec Group	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Smith & Nephew has a net margin of 10.08% compared to Convatec Group's net margin of 4.99%. Smith & Nephew's return on equity of 12.25% beat Convatec Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Convatec Group	4.99%	8.40%	5.01%
Smith & Nephew	10.08%	12.25%	4.51%

Convatec Group pays an annual dividend of GBX 7.25 per share and has a dividend yield of 3.1%. Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.8%. Convatec Group pays out 116.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

In the previous week, Convatec Group had 1 more articles in the media than Smith & Nephew. MarketBeat recorded 2 mentions for Convatec Group and 1 mentions for Smith & Nephew. Convatec Group's average media sentiment score of 1.88 beat Smith & Nephew's score of 0.00 indicating that Convatec Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Convatec Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Smith & Nephew	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.7% of Convatec Group shares are held by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are held by institutional investors. 1.0% of Convatec Group shares are held by insiders. Comparatively, 0.2% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Convatec Group beats Smith & Nephew on 12 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and Smith & Nephew (LON:SN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Smith & Nephew has higher revenue and earnings than Advanced Medical Solutions Group. Smith & Nephew is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Solutions Group	£233.63M	2.63	£11.22M	£1.65	171.21
Smith & Nephew	£7.08B	1.62	£382.79M	£27.77	37.77

Advanced Medical Solutions Group has a beta of 0.753, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Smith & Nephew has a beta of 0.688, suggesting that its share price is 31% less volatile than the broader market.

Smith & Nephew has a net margin of 10.08% compared to Advanced Medical Solutions Group's net margin of 1.58%. Smith & Nephew's return on equity of 12.25% beat Advanced Medical Solutions Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Medical Solutions Group	1.58%	1.44%	2.35%
Smith & Nephew	10.08%	12.25%	4.51%

Advanced Medical Solutions Group presently has a consensus target price of GBX 278.33, suggesting a potential downside of 1.47%. Smith & Nephew has a consensus target price of GBX 1,293.33, suggesting a potential upside of 23.29%. Given Smith & Nephew's higher probable upside, analysts plainly believe Smith & Nephew is more favorable than Advanced Medical Solutions Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Solutions Group	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Smith & Nephew had 1 more articles in the media than Advanced Medical Solutions Group. MarketBeat recorded 1 mentions for Smith & Nephew and 0 mentions for Advanced Medical Solutions Group. Advanced Medical Solutions Group's average media sentiment score of 0.00 equaled Smith & Nephew'saverage media sentiment score.

Company	Overall Sentiment
Advanced Medical Solutions Group	Neutral
Smith & Nephew	Neutral

21.5% of Advanced Medical Solutions Group shares are owned by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are owned by institutional investors. 4.0% of Advanced Medical Solutions Group shares are owned by insiders. Comparatively, 0.2% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Advanced Medical Solutions Group pays an annual dividend of GBX 2.86 per share and has a dividend yield of 1.0%. Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.8%. Advanced Medical Solutions Group pays out 173.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Smith & Nephew beats Advanced Medical Solutions Group on 12 of the 16 factors compared between the two stocks.

How does Smith & Nephew compare to NIOX Group?

Smith & Nephew (LON:SN) and NIOX Group (LON:NIOX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

62.2% of Smith & Nephew shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by company insiders. Comparatively, 5.1% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Smith & Nephew currently has a consensus price target of GBX 1,293.33, suggesting a potential upside of 23.29%. NIOX Group has a consensus price target of GBX 86, suggesting a potential upside of 26.10%. Given NIOX Group's stronger consensus rating and higher probable upside, analysts clearly believe NIOX Group is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Smith & Nephew has a beta of 0.688, meaning that its share price is 31% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

NIOX Group has a net margin of 14.74% compared to Smith & Nephew's net margin of 10.08%. Smith & Nephew's return on equity of 12.25% beat NIOX Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	10.08%	12.25%	4.51%
NIOX Group	14.74%	10.01%	3.95%

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.8%. NIOX Group pays an annual dividend of GBX 1.55 per share and has a dividend yield of 2.3%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 95.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

In the previous week, Smith & Nephew had 1 more articles in the media than NIOX Group. MarketBeat recorded 1 mentions for Smith & Nephew and 0 mentions for NIOX Group. Smith & Nephew's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company	Overall Sentiment
Smith & Nephew	Neutral
NIOX Group	Neutral

NIOX Group has lower revenue, but higher earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	£7.08B	1.62	£382.79M	£27.77	37.77
NIOX Group	£47.50M	6.04	£995.88M	£1.63	41.84

Summary

NIOX Group beats Smith & Nephew on 9 of the 17 factors compared between the two stocks.

How does Smith & Nephew compare to Tristel?

Smith & Nephew (LON:SN) and Tristel (LON:TSTL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Smith & Nephew has a beta of 0.688, indicating that its share price is 31% less volatile than the broader market. Comparatively, Tristel has a beta of 0.352, indicating that its share price is 65% less volatile than the broader market.

62.2% of Smith & Nephew shares are owned by institutional investors. Comparatively, 22.4% of Tristel shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by company insiders. Comparatively, 21.0% of Tristel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tristel has a net margin of 15.88% compared to Smith & Nephew's net margin of 10.08%. Tristel's return on equity of 23.64% beat Smith & Nephew's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	10.08%	12.25%	4.51%
Tristel	15.88%	23.64%	9.89%

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.8%. Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.3%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

Smith & Nephew currently has a consensus target price of GBX 1,293.33, suggesting a potential upside of 23.29%. Given Smith & Nephew's stronger consensus rating and higher possible upside, equities research analysts clearly believe Smith & Nephew is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Smith & Nephew has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	£7.08B	1.62	£382.79M	£27.77	37.77
Tristel	£49.54M	4.20	£6.54M	£16.24	26.67

In the previous week, Smith & Nephew and Smith & Nephew both had 1 articles in the media. Smith & Nephew's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tristel	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Smith & Nephew beats Tristel on 9 of the 16 factors compared between the two stocks.

How does Smith & Nephew compare to EKF Diagnostics?

Smith & Nephew (LON:SN) and EKF Diagnostics (LON:EKF) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

62.2% of Smith & Nephew shares are owned by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by company insiders. Comparatively, 40.2% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Smith & Nephew presently has a consensus target price of GBX 1,293.33, indicating a potential upside of 23.29%. EKF Diagnostics has a consensus target price of GBX 35, indicating a potential upside of 45.83%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe EKF Diagnostics is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Smith & Nephew has a beta of 0.688, indicating that its share price is 31% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, indicating that its share price is 50% less volatile than the broader market.

Smith & Nephew has higher revenue and earnings than EKF Diagnostics. Smith & Nephew is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	£7.08B	1.62	£382.79M	£27.77	37.77
EKF Diagnostics	£51.35M	2.00	£4.68M	£0.58	41.38

Smith & Nephew has a net margin of 10.08% compared to EKF Diagnostics' net margin of 4.86%. Smith & Nephew's return on equity of 12.25% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	10.08%	12.25%	4.51%
EKF Diagnostics	4.86%	3.58%	5.27%

In the previous week, Smith & Nephew and Smith & Nephew both had 1 articles in the media. EKF Diagnostics' average media sentiment score of 0.75 beat Smith & Nephew's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
EKF Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Smith & Nephew beats EKF Diagnostics on 8 of the 15 factors compared between the two stocks.

Get Smith & Nephew News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SN vs. The Competition

Export

Metric	Smith & Nephew	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£11.51B	£5.59B	£7.18B	£2.80B
Dividend Yield	3.66%	1.74%	2.52%	6.26%
P/E Ratio	37.80	20.69	213.76	366.73
Price / Sales	1.63	64.79	573.62	88,658.65
Price / Cash	18.68	32.11	76.68	27.83
Price / Book	1.76	5.72	10.29	6.83
Net Income	£382.79M	£146.93M	£3.50B	£5.88B
7 Day Performance	3.04%	-1.61%	-3.54%	0.47%
1 Month Performance	0.14%	-4.38%	-7.80%	-0.30%
1 Year Performance	-19.91%	0.69%	0.77%	22.00%

Smith & Nephew Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SN Smith & Nephew	3.341 of 5 stars	GBX 1,050 +0.1%	GBX 1,293.33 +23.2%	-20.8%	£11.51B	£7.08B	37.80	18,452	High Trading Volume
CTEC Convatec Group	4.8848 of 5 stars	GBX 217.04 -0.6%	GBX 305.44 +40.7%	-3.0%	£4.16B	£2.49B	35.01	10,000	News Coverage Insider Trade
AMS Advanced Medical Solutions Group	0.2106 of 5 stars	GBX 282.50 +0.4%	GBX 278.33 -1.5%	+23.4%	£615.02M	£233.63M	171.21	10	Positive News
NIOX NIOX Group	1.6787 of 5 stars	GBX 67.20 -0.3%	GBX 86 +28.0%	-9.1%	£282.82M	£47.50M	41.23	92	Positive News Gap Up
TSTL Tristel	N/A	GBX 429.50 +1.1%	N/A	+20.0%	£206.47M	£49.54M	26.45	208

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SN) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Smith & Nephew (SN) Competitors

SN vs. CTEC, AMS, NIOX, TSTL, and EKF

How does Smith & Nephew compare to Convatec Group?

Summary

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Summary

How does Smith & Nephew compare to NIOX Group?

Summary

How does Smith & Nephew compare to Tristel?

Summary

How does Smith & Nephew compare to EKF Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SN vs. The Competition

Smith & Nephew Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Smith & Nephew (SN) Competitors

SN vs. CTEC, AMS, NIOX, TSTL, and EKF

How does Smith & Nephew compare to Convatec Group?

Which has stronger valuation & earnings, CTEC or SN?

Which has more volatility and risk, CTEC or SN?

Do analysts recommend CTEC or SN?

Is CTEC or SN more profitable?

Is CTEC or SN a better dividend stock?

Does the media refer more to CTEC or SN?

Do insiders and institutionals believe in CTEC or SN?

Summary

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Which has preferable earnings & valuation, AMS or SN?

Which has more risk & volatility, AMS or SN?

Is AMS or SN more profitable?

Do analysts prefer AMS or SN?

Does the media favor AMS or SN?

Do insiders and institutionals hold more shares of AMS or SN?

Is AMS or SN a better dividend stock?

Summary

How does Smith & Nephew compare to NIOX Group?

Do insiders and institutionals hold more shares of SN or NIOX?

Do analysts recommend SN or NIOX?

Which has more risk and volatility, SN or NIOX?

Is SN or NIOX more profitable?

Is SN or NIOX a better dividend stock?

Does the media prefer SN or NIOX?

Which has preferable earnings and valuation, SN or NIOX?

Summary

How does Smith & Nephew compare to Tristel?

Which has more risk & volatility, SN or TSTL?

Do institutionals & insiders hold more shares of SN or TSTL?

Is SN or TSTL more profitable?

Is SN or TSTL a better dividend stock?

Do analysts rate SN or TSTL?

Which has stronger earnings & valuation, SN or TSTL?

Does the media refer more to SN or TSTL?

Summary

How does Smith & Nephew compare to EKF Diagnostics?

Do insiders and institutionals have more ownership in SN or EKF?

Do analysts rate SN or EKF?

Which has more volatility & risk, SN or EKF?

Which has better valuation and earnings, SN or EKF?

Is SN or EKF more profitable?

Does the media prefer SN or EKF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SN vs. The Competition

Smith & Nephew Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools